BSE · 531681
Amerise Biosciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹0 Cr — a 3.03% net margin, versus -406.96% the period before.
Shareholding
As of 2026-06-30
- Public100%
33,848 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 1.98× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #362 of 530 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,96,212 Cr | 119.01 | 4.12 | 13.32% | 33.06% |
| Eternal Limited | ₹3,00,898 Cr | 1641.05 | 9.25 | 1.18% | 0.67% |
| BSE Limited | ₹1,44,241 Cr | 183.02 | 21.65 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,15,143 Cr | 77.49 | 1.29 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,13,087 Cr | 369.31 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,092 Cr | 137.04 | 9.54 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹85,165 Cr | 463.41 | 5.31 | 4.55% | 6.55% |
| Meesho Limited | ₹82,526 Cr | — | 18.67 | -28.13% | -10.75% |
| Info Edge (India) Ltd. | ₹80,913 Cr | 142.94 | 2.13 | 3.82% | 0.44% |
| Swiggy Limited | ₹79,315 Cr | — | 4.33 | -22.68% | -18.02% |
| Amerise Biosciences Limited(this company) | ₹7 Cr | — | 1.21 | 29.84% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAmerise Biosciences Limited (symbol: 531681) has a market capitalization of Rs 6 Cr. The company's book value is Rs 0.82 per share. It has no promoter shareholding, with public shareholders holding 100% as of June 30, 2026. The company is currently under GSM and LT-ASM surveillance measures.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +The return on equity (ROE) was 29.84%, reflecting profitability relative to shareholder equity.
- +The number of shareholders increased from 290 in September 2016 to 33,848 in June 2026.
Negatives
- −The company's profit margin is 0%, indicating no profit generation relative to revenue as of the latest disclosed period.
- −Promoter shareholding is 0% as of June 30, 2026.
- −Earnings per share (EPS) was negative in March 2024 (-0.02) and March 2023 (-0.02).
- −The company is currently under GSM and LT-ASM surveillance measures.
Financial performance
Amerise Biosciences Limited reported revenue of Rs 0.188 Cr in March 2025, which followed a revenue of Rs 0.0359 Cr in March 2024. Net profit was Rs 0.0057 Cr in March 2025, after a net loss of Rs 0.1461 Cr in March 2024. Over the last five annual periods, revenue increased from Rs -0.1689641 Cr in March 2021 to Rs 0.188 Cr in March 2025.
Profitability & returns
The company's profit margin was 0% as of the latest disclosed period. Return on capital employed (ROCE) stood at 0.3818%, and return on equity (ROE) was 29.84%. Earnings per share (EPS) was 0.0009 in March 2025. In previous years, EPS recorded were -0.02 in March 2024 and -0.02 in March 2023.
Balance sheet
Amerise Biosciences Limited has a debt-to-equity ratio of 0, indicating no debt on its books. The book value per share is Rs 0.82.
Ownership & pledges
There is no promoter holding (0%) and no institutional holding (0%). The total number of shareholders was 33,848 in June 2026. This contrasts with earlier periods like September 2016, which had 290 shareholders.
Regulatory & surveillance
Amerise Biosciences Limited is currently subject to surveillance measures, specifically GSM and LT-ASM. This indicates heightened monitoring by regulatory authorities.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Amerise Biosciences Limitedshare price & fundamentals